Rheumatoid Arthritis

You have full text access to this OnlineOpen article

The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis

  1. Daniel H. Solomon1,†,*,
  2. Joel S. Finkelstein2,
  3. Nancy Shadick1,‡,
  4. Meryl S. LeBoff1,§,
  5. Carl S. Winalski3,¶,
  6. Margaret Stedman1,
  7. Roberta Glass1,
  8. M. Alan Brookhart1,
  9. Michael E. Weinblatt1,‖,
  10. Ellen M. Gravallese4,††

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24551

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 6, pages 1624–1631, June 2009

Additional Information

How to Cite

Solomon, D. H., Finkelstein, J. S., Shadick, N., LeBoff, M. S., Winalski, C. S., Stedman, M., Glass, R., Brookhart, M. A., Weinblatt, M. E. and Gravallese, E. M. (2009), The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis & Rheumatism, 60: 1624–1631. doi: 10.1002/art.24551

Author Information

  1. 1

    Brigham and Women's Hospital, Boston, Massachusetts

  2. 2

    Massachusetts General Hospital, Boston

  3. 3

    Cleveland Clinic Foundation, Cleveland, Ohio

  4. 4

    University of Massachusetts Medical Center, Worcester

  1. †

    Dr. Solomon has received research grants from Abbott and Amgen, and has served as an unpaid member of the Data Safety and Monitoring Board and the Trial Executive Committee for Pfizer.

  2. ‡

    Dr. Shadick has received research grants from the Amgen Foundation, the Bristol-Myers Squibb Foundation, Millennium Pharmaceuticals, Biogen Idec, and Crescendo Therapeutics.

  3. §

    Dr. LeBoff owns stock or stock options in GE and Amgen.

  4. Dr. Winalski owns stock or stock options in Pfizer, has received research support from Abbott, and has served as an investigator for research at the Cleveland Clinic funded through a contract with Abbott.

  5. ‖

    Dr. Weinblatt has received consulting fees and/or research funding from Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Genentech, Millennium Pharmaceuticals, and Riley Genomics (less than $10,000 each). He has received consulting fees from Crescendo Therapeutics (less than $10,000), and from other companies that are unrelated to this study. This information is on file at the journal.

  6. ††

    Dr. Gravallese has received consulting fees from Abbott (less than $10,000). The BRASS registry was supported by Millennium Pharmaceuticals, Riley Genomics, and Biogen Idec.

*Division of Rheumatology, Brigham and Women's Hospital, 75 Francis Street, PBB-B3, Boston, MA 02115

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 25 FEB 2009
  4. Manuscript Received: 9 JUN 2008

Funded by

  • NIH. Grant Numbers: AG-027066, AR-047782, AR-055989, K24-DK-02759, AR-047665
  • CDC
  • Worcester Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (81K)

REFERENCES

  • 1
    Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003; 48: 917–26.
    Direct Link:
  • 2
    Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 269–81.
  • 3
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11.
  • 4
    Van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 3104–12.
    Direct Link:
  • 5
    Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 2004; 16: 419–27.
  • 6
    Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 943–51.
  • 7
    Haugeberg G, Lodder MC, Lems WF, Uhlig T, Orstavik RE, Dijkmans BA, et al. Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50-70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study. Ann Rheum Dis 2004; 63: 1331–4.
  • 8
    Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004; 164: 543–55.
  • 9
    Solomon DH, Stedman M, Licari A, Weinblatt ME, Maher N, Shadick N. Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. Arthritis Rheum 2007; 57: 234–9.
    Direct Link:
  • 10
    Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28: 1326–35.
    Direct Link:
  • 11
    Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001; 60: 817–27.
  • 12
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244–57.
  • 13
    Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH. Comparative measurement sensitivity of short and longer health status instruments. Med Care 1992; 30: 917–25.
  • 14
    Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2350–5.
  • 15
    Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002; 46: 2847–56.
    Direct Link:
  • 16
    Jensen T, Hansen M, Jensen KE, Podenphant J, Hansen TM, Hyldstrup L. Comparison of dual X-ray absorptiometry (DXA), digital X-ray radiogrammetry (DXR), and conventional radiographs in the evaluation of osteoporosis and bone erosions in patients with rheumatoid arthritis. Scand J Rheumatol 2005; 34: 27–33.
  • 17
    Stewart A, Mackenzie LM, Black AJ, Reid DM. Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology (Oxford) 2004; 43: 1561–4.
  • 18
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977; 18: 481–91.
  • 19
    Forslind K, Keller C, Svensson B, Hafstrom I, Group BS. Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol 2003; 30: 2590–6.
  • 20
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum 2005; 52: 3381–90.
    Direct Link:
  • 21
    Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68: 330–6.
  • 22
    Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007; 66: 1221–6.
  • 23
    Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796–806.
  • 24
    Patel S, Farragher T, Symmons D. Reply to letter by Lippi et al commenting on the relationship between serum vitamin D levels and levels of inflammation markers [letter]. Arthritis Rheum 2008; 58: 1882.
    Direct Link:
  • 25
    Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun Rev 2007; 7: 59–64.
  • 26
    Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005; 44: 1546–8.
  • 27
    Guler-Yuskel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008; 67: 823–8.
  • 28
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodsen GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821–31.
  • 29
    Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al, and the Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299–309.
    Direct Link:
View Full Article (HTML) Get PDF (81K)